| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC4977 | Sun13837 | Novel fibroblast growth factor receptor modulator for treating neurodegenerative diseases |
|
| DCC4978 | Sun-c5174 | 5-HT2 antagonist |
|
| DCC4979 | Supradamal | Potent Inhibitor of Plasmodium FK506 Binding Protein 35 (FKBD35), also act as a HIV inhibitor |
|
| DCC4980 | suvanine | Antagonist of the mammalian bile acid sensor farnesoid-X-receptor (FXR) |
|
| DCC4981 | Sv-293 | Selective D2 dopamine receptor antagonist |
|
| DCC4982 | Sv-iii-130s | D2 dopamine receptor partial agonist in adenylyl cyclase inhibition assay and antagonist in the GIRK and phospho ERK1/2 assays |
|
| DCC4983 | Sw208108 | Novel clickable tumor-specific irreversible inhibitor of stearoyl CoA desaturase (SCD) |
|
| DCC4984 | Swainsonine | Natural potent alpha-mannosidase inhibitor, exhibiting antimetastatic, antiproliferative, and immunomodulatory activities |
|
| DCC4985 | swertisin | Potent differentiating agent |
|
| DCC4986 | S-y048 | Novel selective OXE receptor antagonist |
|
| DCC4987 | Sy-5609 | Novel highly potent and selective CDK7 inhibitor, demonstrating broad anti-tumor activity in vivo |
|
| DCC4988 | Syk-524 | Novel universal opioid receptor agonist |
|
| DCC4989 | Syk-in-ii | Novel inhibitor of the Syk kinase (spleen tyrosine kinase) |
|
| DCC4990 | Syn-1 Peptide | Novel potent and specific inhibitor of syncytin-mediated cell fusion, completely blocking cell fusion at 1.6 μg/ml |
|
| DCC4991 | Syn-1 Scr Peptide | Negative control of Syn-1 peptide, having the same amino acid composition as Syn-1 peptide, but a scrambled sequence |
|
| DCC4992 | syn22269076 | Novel Mycobacterium tuberculosis growth inhibitor |
|
| DCC4993 | Synstab A | Novel microtubule-stablizer |
|
| DCC4994 | Synthalin Dihydrochloride | K+ channel blocker |
|
| DCC4995 | Szu101 Featured | Novel TLR7 agonist via immune response induction and tumor microenvironment modulation |
|
| DCC4996 | Szv558 | Potent inhibitor of both rodent and human MAO-B, proved to be safe in high doses with no hERG and mutagenic activities and demonstrated neuroprotection in an in vivo chronic model of PD |
|
| DCC4997 | T0511-4424 | Novel COX-2 inhibitor |
|
| DCC4998 | T-0632 | Potent and selective CCKA receptor antagonist |
|
| DCC4999 | T-10106 | Novel potent PPARγ antagonist with much improved drug-like properties and promising pharmacokinetic profile |
|
| DCC5000 | T16a(inh)-b01 | Selective class B inhibitor of the Ca -activated Cl- Channel, Ano1(TMEM16A) |
|
| DCC5001 | T16a(inh)-d01 | Selective class D inhibitor of the Ca -activated Cl- Channel, Ano1(TMEM16A) |
|
| DCC5002 | T-2 Toxin Triol | Type-A trichothecene mycotoxin |
|
| DCC5003 | T3ss Inhibitor Iii-7 | Novel inhibitor of the type III secretion system (T3SS), acting as a anti-microbial agent against Xanthomonas oryzae pv. oryzae (Xoo) |
|
| DCC5004 | t5660136 | Novel Inhibitor of Adenovirus Gene Transfer |
|
| DCC5005 | t5660138 | Novel Inhibitor of Adenovirus Gene Transfer |
|
| DCC5006 | T5975164 | Inhibitor of HIV-1 Assembly that Targets the Phosphatidylinositol (4,5)-bisphosphate Binding Site of the HIV-1 Matrix Protein |
|
